FibroGen (NASDAQ:FGEN) Share Price Passes Below 50-Day Moving Average of $13.04

Shares of FibroGen, Inc. (NASDAQ:FGENGet Rating) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $13.04 and traded as low as $12.01. FibroGen shares last traded at $12.19, with a volume of 690,148 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on FGEN. Cowen boosted their price target on shares of FibroGen to $14.00 in a research report on Monday, August 15th. StockNews.com cut shares of FibroGen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. Finally, The Goldman Sachs Group reduced their price target on shares of FibroGen from $9.00 to $8.00 and set a “sell” rating on the stock in a research report on Tuesday, May 24th.

FibroGen Stock Down 7.1 %

The firm’s 50-day moving average is $13.04 and its 200-day moving average is $11.72. The company has a market cap of $1.14 billion, a PE ratio of -5.14 and a beta of 0.88.

FibroGen (NASDAQ:FGENGet Rating) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The business had revenue of $29.81 million for the quarter, compared to analyst estimates of $36.15 million. During the same quarter in the previous year, the firm posted ($1.45) earnings per share. FibroGen’s quarterly revenue was up 22.3% on a year-over-year basis. As a group, equities research analysts anticipate that FibroGen, Inc. will post -3 EPS for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Several hedge funds have recently bought and sold shares of the business. Walleye Capital LLC boosted its stake in FibroGen by 16.6% during the second quarter. Walleye Capital LLC now owns 184,406 shares of the biopharmaceutical company’s stock worth $1,947,000 after acquiring an additional 26,315 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of FibroGen by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 736,550 shares of the biopharmaceutical company’s stock worth $7,777,000 after buying an additional 60,482 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of FibroGen by 16.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 20,362 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 2,939 shares in the last quarter. Caption Management LLC bought a new position in shares of FibroGen in the second quarter worth approximately $3,432,000. Finally, PDT Partners LLC lifted its stake in shares of FibroGen by 6.8% in the second quarter. PDT Partners LLC now owns 171,911 shares of the biopharmaceutical company’s stock worth $1,815,000 after buying an additional 11,008 shares in the last quarter. Institutional investors own 74.76% of the company’s stock.

About FibroGen

(Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Articles

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.